Expression of FK506‐binding protein 51 (FKBP51) in Mycosis fungoides

Mycosis fungoides (MF) is the major subtype of cutaneous T‐cell lymphomas (CTCL). It usually has a prolonged indolent clinical course with a minority of cases acquiring a more aggressive biological profile and resistance to conventional therapies, partially attributed to the persistent activation of nuclear factor‐kappa B (NF‐κB) pathway. In the last decade, several papers suggested an important role for the FK506‐binding protein 51 (FKBP51), an immunophilin initially cloned in lymphocytes, in the control of NF‐κB pathway in different types of human malignancies.

[1]  S. Staibano,et al.  FKBP51 Immunohistochemical Expression: A New Prognostic Biomarker for OSCC? , 2017, International journal of molecular sciences.

[2]  R. Gniadecki,et al.  TP53 Gene Status Affects Survival in Advanced Mycosis Fungoides , 2016, Front. Med..

[3]  A. Bracher,et al.  Rapid, Structure-Based Exploration of Pipecolic Acid Amides as Novel Selective Antagonists of the FK506-Binding Protein 51. , 2016, Journal of medicinal chemistry.

[4]  R. Cowan,et al.  Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D. Schatz,et al.  Genomic landscape of cutaneous T cell lymphoma , 2015, Nature Genetics.

[6]  P. Ascierto,et al.  Immunomodulatory pathways regulate expression of a spliced FKBP51 isoform in lymphocytes of melanoma patients , 2015, Pigment cell & melanoma research.

[7]  M. Masullo,et al.  FKBP51 employs both scaffold and isomerase functions to promote NF-κB activation in melanoma , 2015, Nucleic acids research.

[8]  I. Poser,et al.  FBXW7 and USP7 regulate CCDC6 turnover during the cell cycle and affect cancer drugs susceptibility in NSCLC , 2015, Oncotarget.

[9]  C. Chao,et al.  Transcriptomic profiling of taxol-resistant ovarian cancer cells identifies FKBP5 and the androgen receptor as critical markers of chemotherapeutic response , 2014, Oncotarget.

[10]  I. Vancurova,et al.  NFκB function and regulation in cutaneous T-cell lymphoma. , 2013, American journal of cancer research.

[11]  S. Staibano,et al.  FK506 binding protein 51 positively regulates melanoma stemness and metastatic potential , 2013, Cell Death and Disease.

[12]  G. de Rosa,et al.  Tissue Microarray-Based Evaluation of Chromatin Assembly Factor-1 (CAF-1)/p60 as Tumour Prognostic Marker , 2012, International journal of molecular sciences.

[13]  M. Karin,et al.  NF‐κB and the link between inflammation and cancer , 2012, Immunological reviews.

[14]  P. Porcu,et al.  Evolving Insights in the Pathogenesis and Therapy of Cutaneous T‐cell lymphoma (Mycosis Fungoides and Sezary Syndrome) , 2011, British journal of haematology.

[15]  M. Wasik,et al.  Simultaneous Inhibition of mTOR-Containing Complex 1 (mTORC1) and MNK Induces Apoptosis of Cutaneous T-Cell Lymphoma (CTCL) Cells , 2011, PloS one.

[16]  G. de Rosa,et al.  Immunohistochemical analysis of FKBP51 in human cancers. , 2011, Current opinion in pharmacology.

[17]  J. Scammell,et al.  Organization and function of the FKBP52 and FKBP51 genes. , 2011, Current opinion in pharmacology.

[18]  M. Walkinshaw,et al.  Targeting FKBP isoforms with small-molecule ligands. , 2011, Current opinion in pharmacology.

[19]  E. R. Sánchez,et al.  FKBP51-a selective modulator of glucocorticoid and androgen sensitivity. , 2011, Current opinion in pharmacology.

[20]  Wolfram Sterry,et al.  Pathogenesis of Mycosis fungoides , 2011, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[21]  Z. Lou,et al.  The role of FKBP5 in cancer aetiology and chemoresistance , 2010, British Journal of Cancer.

[22]  G. de Rosa,et al.  The proliferation marker Chromatin Assembly Factor-1 is of clinical value in predicting the biological behaviour of salivary gland tumours. , 2010, Oncology reports.

[23]  J. Scarisbrick,et al.  Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  S. Romano,et al.  FK506 binding proteins as targets in anticancer therapy. , 2010, Anti-cancer agents in medicinal chemistry.

[25]  H. Friess,et al.  Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. , 2010, JAMA.

[26]  C. Klemke,et al.  Cutaneous T‐cell lymphoma cells are sensitive to rapamycin , 2010, Experimental dermatology.

[27]  S. Staibano,et al.  FK506-binding protein 51 is a possible novel tumoral marker , 2010, Cell Death and Disease.

[28]  G. de Rosa,et al.  Overexpression of Chromatin Assembly Factor-1/p60 helps to predict the prognosis of melanoma patients , 2010, BMC Cancer.

[29]  J. Buchner,et al.  The Hsp90 Cochaperone, FKBP51, Increases Tau Stability and Polymerizes Microtubules , 2010, The Journal of Neuroscience.

[30]  C. Sander,et al.  Classification of cutaneous lymphomas – an update , 2010, Histopathology.

[31]  P. Chieffi,et al.  Overexpression of chromatin assembly factor‐1 (CAF‐1) p60 is predictive of adverse behaviour of prostatic cancer , 2009, Histopathology.

[32]  S. Whittaker,et al.  A genomic and expression study of AP‐1 in primary cutaneous T‐cell lymphoma: evidence for dysregulated expression of JUNB and JUND in MF and SS , 2008, Journal of cutaneous pathology.

[33]  J. Skolnick,et al.  Structure‐based classification of 45 FK506‐binding proteins , 2008, Proteins.

[34]  T. Mikkelsen,et al.  FK506 binding protein mediates glioma cell growth and sensitivity to rapamycin treatment by regulating NF-kappaB signaling pathway. , 2008, Neoplasia.

[35]  G. Courtois,et al.  Inhibition of IκB Kinase Subunit 2 in Cutaneous T-Cell Lymphoma Down-Regulates Nuclear Factor-κB Constitutive Activation, Induces Cell Death, and Potentiates the Apoptotic Response to Antineoplastic Chemotherapeutic Agents , 2008, Clinical Cancer Research.

[36]  Michael Karin,et al.  NF-kappaB and cancer-identifying targets and mechanisms. , 2008, Current opinion in genetics & development.

[37]  C. Mignogna,et al.  Chromatin assembly factor‐1 (CAF‐1)‐mediated regulation of cell proliferation and DNA repair: a link with the biological behaviour of squamous cell carcinoma of the tongue? , 2007, Histopathology.

[38]  U. Döbbeling.  Transcription factor profiling shows new ways towards new treatment options of cutaneous T cell lymphomas. , 2007, Current drug discovery technologies.

[39]  G. Courtois,et al.  Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis. , 2006, Blood.

[40]  V. Poggi,et al.  Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells. , 2005, Blood.

[41]  T. Kuzel,et al.  The spectrum of cutaneous T-cell lymphomas: new insights into biology and therapy , 2005, Current opinion in hematology.

[42]  Nicola Pimpinelli,et al.  WHO-EORTC classification for cutaneous lymphomas. , 2005, Blood.

[43]  L. Showe,et al.  Immunopathogenesis and therapy of cutaneous T cell lymphoma. , 2005, The Journal of clinical investigation.

[44]  S. Venuta,et al.  Rapamycin inhibits doxorubicin-induced NF-kappaB/Rel nuclear activity and enhances the apoptosis of melanoma cells. , 2004, European journal of cancer.

[45]  Sankar Ghosh,et al.  Signaling to NF-kappaB. , 2004, Genes & development.

[46]  P. Nowell,et al.  BCL2 and JUNB abnormalities in primary cutaneous lymphomas , 2004, The British journal of dermatology.

[47]  M. Karin,et al.  Inhibition of NF-κB in cancer cells converts inflammation- induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression , 2004 .

[48]  Andreas Sommer,et al.  NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression , 2004 .

[49]  M. Wasik,et al.  In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3 , 2004, Leukemia.

[50]  M. Karin,et al.  The IKK/NF-κB activation pathway—a target for prevention and treatment of cancer , 2004 .

[51]  Giulio Superti-Furga,et al.  A physical and functional map of the human TNF-α/NF-κB signal transduction pathway , 2004, Nature Cell Biology.

[52]  P. Taylor,et al.  Structures of immunophilins and their ligand complexes. , 2003, Current topics in medicinal chemistry.

[53]  S. Whittaker,et al.  Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas. , 2003, Blood.

[54]  W. Vainchenker,et al.  Overexpression of FKBP51 in idiopathic myelofibrosis regulates the growth factor independence of megakaryocyte progenitors. , 2002, Blood.

[55]  Michael Karin,et al.  NF-κB at the crossroads of life and death , 2002, Nature Immunology.

[56]  S. Alkan,et al.  Constitutive expression of NF-kappa B is a characteristic feature of mycosis fungoides: implications for apoptosis resistance and pathogenesis. , 2000, Human pathology.

[57]  R. Willemze,et al.  Expression of Fas and Fas‐ligand in primary cutaneous T‐cell lymphoma (CTCL): association between lack of Fas expression and aggressive types of CTCL , 2000, The British journal of dermatology.

[58]  C. Geisler,et al.  Inhibition of constitutively activated Stat3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cells , 1999, Leukemia.

[59]  M. Martin,et al.  Tissue distribution and abundance of human FKBP51, and FK506-binding protein that can mediate calcineurin inhibition. , 1997, Biochemical and biophysical research communications.

[60]  D. Goeddel,et al.  The tumor necrosis factor receptor 2 signal transducers TRAF2 and c-IAP1 are components of the tumor necrosis factor receptor 1 signaling complex. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[61]  W. Yeh,et al.  Identification and characterization of an immunophilin expressed during the clonal expansion phase of adipocyte differentiation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[62]  M. Martin,et al.  FKBP51, a novel T-cell-specific immunophilin capable of calcineurin inhibition , 1995, Molecular and cellular biology.

[63]  K. Wright,et al.  Function of NF-kappa B/Rel binding sites in the major histocompatibility complex class II invariant chain promoter is dependent on cell-specific binding of different NF-kappa B/Rel subunits , 1994, Molecular and cellular biology.

[64]  P. Baeuerle,et al.  Purification, reconstitution, and I kappa B association of the c-Rel-p65 (RelA) complex, a strong activator of transcription , 1994, Molecular and cellular biology.

[65]  M. Greene,et al.  Mycosis fungoides: epidemiologic observations. , 1979, Cancer treatment reports.

[66]  S. Staibano,et al.  Nucleotide Excision Repair and head and neck cancers. , 2016, Frontiers in bioscience.

[67]  S. Staibano,et al.  Role of FK506-binding protein 51 in the control of apoptosis of irradiated melanoma cells , 2010, Cell Death and Differentiation.

[68]  M. Karin,et al.  Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. , 2004, Cancer cell.

[69]  M. Karin,et al.  The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. , 2004, Cancer letters.

[70]  G Fischer,et al.  Regulation of peptide bond cis/trans isomerization by enzyme catalysis and its implication in physiological processes. , 2003, Reviews of physiology, biochemistry and pharmacology.

[71]  M. Karin,et al.  Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. , 2000, Annual review of immunology.

[72]  M J May,et al.  NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. , 1998, Annual review of immunology.